For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 0 | 0 | - | - |
| Research and development | 34,068,000 | 42,658,000 | 35,942,000 | 42,976,333.333 |
| General and administrative | 18,351,000 | 25,020,000 | 28,446,000 | 24,950,666.667 |
| Restructuring | -172,000 | 3,471,000 | - | - |
| Total operating expenses | 52,247,000 | 71,149,000 | 64,388,000 | 67,927,000 |
| Loss from operations | -52,247,000 | -71,149,000 | -64,388,000 | -67,927,000 |
| Interest expense | 473,000 | 473,000 | 472,000 | 471,666.667 |
| Interest and other income, net | 709,000 | 483,000 | 1,336,000 | 2,313,333.333 |
| Accretion of discount on investments, net | 1,679,000 | 2,220,000 | 2,190,000 | 2,076,333.333 |
| Net loss | -50,332,000 | -68,919,000 | -61,334,000 | -64,009,000 |
| Earnings per share, basic, total | -0.45 | -0.62 | -0.56 | -0.673 |
| Earnings per share, diluted, total | -0.45 | -0.62 | -0.56 | -0.673 |
| Weighted average number of shares outstanding, basic, total | 111,571,136 | 111,019,647 | 110,093,461 | 216,427.333 |
| Weighted average number of shares outstanding, diluted, total | 111,571,136 | 111,019,647 | 110,093,461 | 216,427.333 |
ROCKET PHARMACEUTICALS, INC. (RCKT)
ROCKET PHARMACEUTICALS, INC. (RCKT)